Jeannie T. Lee
Direktor/Vorstandsmitglied bei GSK PLC
Profil
Jeannie T.
Lee is the founder of Translate Bio, Inc. (founded in 2011) and Fulcrum Therapeutics, Inc. (founded in 2015).
She is currently the Director at The Genetics Society of America and a Non-Executive Director at GSK Plc (starting in 2024).
Dr. Lee has an undergraduate degree from Harvard University and a doctorate from Perelman School of Medicine.
Aktive Positionen von Jeannie T. Lee
| Unternehmen | Position | Beginn |
|---|---|---|
| GSK PLC | Direktor/Vorstandsmitglied | 04.03.2024 |
| The Genetics Society of America | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Jeannie T. Lee
| Unternehmen | Position | Ende |
|---|---|---|
| TRANSLATE BIO, INC. | Gründer | - |
| FULCRUM THERAPEUTICS, INC. | Gründer | - |
Ausbildung von Jeannie T. Lee
| Harvard University | Undergraduate Degree |
| Perelman School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| FULCRUM THERAPEUTICS, INC. | Health Technology |
| GSK PLC | Health Technology |
| Private Unternehmen | 2 |
|---|---|
| The Genetics Society of America | |
Translate Bio, Inc.
 Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
